Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

Therapeutic approaches to slow or block the progression of Parkinson disease (PD) do not exist. Genetic and biochemical studies implicate α-synuclein and leucine-rich repeat kinase 2 (LRRK2) in late-onset PD. LRRK2 kinase activity has been linked to neurodegenerative pathways. However, the therapeut...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Biol Chem
Autors principals: Daher, João P. L., Abdelmotilib, Hisham A., Hu, Xianzhen, Volpicelli-Daley, Laura A., Moehle, Mark S., Fraser, Kyle B., Needle, Elie, Chen, Yi, Steyn, Stefanus J., Galatsis, Paul, Hirst, Warren D., West, Andrew B.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Biochemistry and Molecular Biology 2015
Matèries:
Neurobiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528108/
https://ncbi.nlm.nih.gov/pubmed/26078453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M115.660001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars